Increasing Virulence in Leprosy Indicated by Global
To the Editor: The November 2017 issue of Emerging Infectious Diseases had 3 articles about leprosy, including these topics: a United States-born patient who tested positive for Mycobacterium lepromatosis (1); a lethal case of Mycobacterium leprae manifested as Lucio's phenomenon in Peru (2); and pointing out that leprosy is an emerging disease in the eastern United States, including autochthonous cases without exposure to armadillos (3), which were previously shown to be a zoonotic source of transmission in the United States (4). Not only is leprosy not disappearing in the United States and globally, but the signs are pointing to a more virulent mycobacterial infection that is likely to be a microbial adaptation to the global use of multidrug therapy, as previously reported (5).
Lucio's phenomenon is fortunately rare; there is no proven effective therapy for this type 3 reaction in leprosy patients. Historically, Lucio's phenomenon was confined to Mexico, mostly in cases of diffuse lepromatous leprosy, also referred to as "Leprosy bonita." In recent years, it has
